期刊文献+

脂蛋白和C反应蛋白对单核细胞趋化蛋白-1的影响 被引量:1

Effects of Lipoprotein and C-reactive Protein on the Expression of Monocyte Chemoattractant Protein-1 and C-C Chemokine Receptor 2
原文传递
导出
摘要 目的探讨单核细胞趋化蛋白-1(MCP-1)及其受体趋化因子受体2(CCR-2)经动脉粥样硬化相关因素刺激后表达量的变化情况。方法密度梯度离心法从健康成人外周血中分离获得单个核细胞,体外培养48h。给予氧化低密度脂蛋白(ox-LDL)、C反应蛋白(CRP)及高密度脂蛋白(HDL)进行干预。干预后用实时荧光定量RT-PCR技术检测单核细胞MCP-1mRNA和CCR2mRNA的含量,ELISA法检测MCP-1蛋白含量。结果ox-LDL+CRP组、ox-LDL、CRP处理组MCP-1和CCR2mRNA表达水平和MCP-1蛋白含量明显高于对照组(P<0.05)。而经HDL处理的单核细胞表达MCP-1和CCR2mRNA水平下调,MCP-1蛋白含量低于对照组(P<0.05)。结论在体外培养的条件下,CRP和ox-LDL可以促进MCP-1和CCR2mRNA表达,继而导致MCP-1含量增加,增强炎症反应的范围和强度。HDL可以有效的抑制MCP-1的表达。 Objective To explore the modulation effect of atherosclerosis related factors on the expressions of monocyte chemoattractant protein-1 and its recpetor C-C chemokine receptor 2 (CCR2). Method Healthy human peripheral mononuelear blood cells (PBMCs) were collected from femoral vessel and isolated by density gradient centrifugation. After cultured for 48 h, the cells were treated with oxidized low density lipoprotein (ox-LDL), C- reactive protein (CRP)or high density lipoprotein (HDL). Real-time Q-PCR was performed to test the mRNA expression of MCP-1 and CCR2. Enzyme linked immunosorbent assay was utilized for measuring level of MCP-1 protein. Result Compared with the control, CRP and ox-LDL enhanced the mRNA expression of MCP-1 and CCR2 and level of MCP-1 protein in vitro (P〈0.05). HDL attenuated the expression of both mRNA and the level of MCP-1 (P〈0.05). Conclusion CRP and ox-LDL enhanced the mRNA expressions of MCP-1 and CCR2 in vitro, leading to the increase of MCP-1 protein level and extension of inflammatory response. HDL efficiently inhibited the expression of MCP-1.
出处 《热带医学杂志》 CAS 2009年第6期618-621,共4页 Journal of Tropical Medicine
基金 广东省自然科学基金(No.06024444)
关键词 C反应蛋白 脂蛋白 炎症 趋化因子 动脉粥样硬化 C-reactive protein lipoprotein inflammation chemokine atherosclerosis
  • 相关文献

参考文献17

  • 1Hoogeveen RC, Morrison A, Boerwinkle E, et al. Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis risk in communities study [J]. Atherosclerosis, 2005,183 (2) : 301- 307.
  • 2Arakelyan A, Petrkova J, Hermanova Z, et al. Serum levels of the MCP-1 ehemokine in patients with ischemic stroke and myocardial infarction [J ]. Mediators hfflamm, 2005 ( 3 ) : 175 - 179.
  • 3Apostolakis S, Papadakis EG, Krambovitis E, et al. Chemokines in vascular pathology (review) [J]. Int J Mol Med, 2006,17(5 ) : 691-701.
  • 4Mackness B, Hine D, Liu Y, et al. Paraoxonase-1 inhibits oxidised LDL-induced MCP-I production by endothelial cells [ J ]. Biochem Biophys Res Commun, 2004,318 ( 3 ) : 680-683.
  • 5Ma J, Wang Q, Fei T, et al. MCP-1 mediates TGF-beta- induced angiogenesis by stimulating vascular smooth muscle cell migration [ J ]. Blood, 2007,109 (3) : 987-994.
  • 6Kim CS, Park HS, Kawada. T, et al. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters [J]. Int J Obes (Lond), 2006,30(9) : 1347-1355.
  • 7Pasini AF, Anselmi M, Garbin U, et al. Enhanced levels of oxidized low-density lipoprotein prime monocytes to cytokine overproduction via upregulation of CD14 and toll-like receptor 4 in unstable angina [J]. Arterioscler Thromb Vasc Biol, 2007,27 (9) : 1991 - 1997.
  • 8Veillard NR, Steffens S, Pelli G, et al. Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo[J]. Circulation,2005,112(6) :870-878.
  • 9Biasucci LM. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper [ J ]. Circulation, 2004, 110 (25) : e560-e567.
  • 10Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease [J]. N Engl J Med, 2004,350(14) : 1387-139.7.

同被引文献5

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部